Home・Stock List・Pharming Group NV

P
Pharming Group NV

Closed

0.986 -0.6

Buy Sell

Overview

Share price change

24h

Current

Min

0.975

Max

1.004

Key metrics
By Trading Economics
Income	6.7M 1.6M
Sales	19M 90M
P/E Sector Avg	99.38 57.371
EPS	0.002
Profit margin	1.744
Employees	407
EBITDA	7.1M 5M

Dividends
By Acuity
Next Earnings	5 Nov 2026

Market Stats
By TradingEconomics
Market Cap	-95M 703M
Previous open	1.59
Previous close	0.986

Pharming Group NV Chart

Past performance is not a reliable indicator of future results.

Related News

23 Aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid broader financial trends, while concerns over U.S. national debt and rising bond yields prompt Treasury interventions ahead of key economic data releases.

23 Aug 2026, 23:51 UTC

Bitcoin and Ethereum rise amid concerns over U.S. national debt and bond market pressures, while Asian stocks anticipate recovery following positive U.S. market performance.

23 Aug 2026, 23:51 UTC

Bitcoin and Ethereum rise as U.S. national debt hits $40 trillion, prompting concerns over economic stability and upcoming key economic data releases.

23 Aug 2026, 23:51 UTC

Cryptocurrency prices rise amid U.S. national debt concerns and bond market volatility, as investors brace for major earnings reports and geopolitical tensions.

23 Aug 2026, 23:51 UTC

Australia's Construction Output Expected to Rise 0.4% Amid Cautious Investor Sentiment Ahead of August Release

23 Aug 2026, 23:51 UTC

Australia's RBA Trimmed Mean CPI Release on August 26, 2026, Expected to Reveal Key Insights into Core Inflation Trends Amid Global Economic Uncertainty.

23 Aug 2026, 23:51 UTC

Australia's Inflation Rate Expected to Drop Slightly to 3.2% Amid Economic Shifts and Market Volatility Concerns

23 Aug 2026, 23:51 UTC

Macro News

Bitcoin is higher today, continuing its upward trend since Saturday. Positive sentiment follows Wall Street's rebound amid declining interest rates and rising gold prices.

23 Aug 2026, 23:51 UTC

Japan's Industrial Production Data Release on August 30 Expected to Show Continued Growth Amid Market Concerns.

23 Aug 2026, 23:51 UTC

Japan's Retail Sales YoY Data Release on August 30 Expected to Show Significant Rebound Amid Mixed Economic Sentiment and Recent Stock Market Decline.

23 Aug 2026, 23:41 UTC

Canada's Monthly GDP Growth Expected Amid Trade Tensions and Inflation Concerns Ahead of August 28 Release.

23 Aug 2026, 23:41 UTC

Bank of Korea's Upcoming Interest Rate Decision Sparks Optimism Amid KOSPI Rally and Global Economic Trends

23 Aug 2026, 23:41 UTC

Canada's GDP Growth Rate Faces Caution Amid Escalating U.S. Trade Tensions and Tariff Concerns Ahead of August 28 Release

23 Aug 2026, 23:41 UTC

Canada's Q2 2026 GDP Growth Rate Release Amidst U.S. Trade Tensions and Infrastructure Boosts Scheduled for August 28, Heightening Market Scrutiny.

23 Aug 2026, 23:31 UTC

RBA Bulletin Release on August 27, 2026 Sparks Anticipation Amid Global Decline in Interest Rates and Market Fluctuations.

23 Aug 2026, 23:21 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Amid Mixed Sentiment and Economic Growth Concerns

23 Aug 2026, 23:21 UTC

U.S. Goods Trade Balance Expected to Hit $99 Billion Deficit Amid Rising U.S.-Canada Tariff Tensions

23 Aug 2026, 23:21 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% in July Amid Mixed Market Sentiment Ahead of August Release

23 Aug 2026, 23:21 UTC

Canada's Current Account Deficit Expected to Reach -5.5 Billion CAD in Q2 2026 Amid Trade Tensions with U.S.

23 Aug 2026, 23:21 UTC

The CAD/CHF currency pair is lower during after-market hours, reflecting a decline since Friday's close amid notable fluctuations in its one-month trading range.

23 Aug 2026, 23:21 UTC

Correlated Moves

XRP is rising during Sunday’s session, supported by Bitcoin's upward movement. The asset has gained significantly since Saturday and remains above its 20-day moving average.

23 Aug 2026, 23:11 UTC

EUR/NZD is trading higher in after-market hours, continuing a gradual increase since Friday's close, despite a recent trend of lower closes.

23 Aug 2026, 23:11 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Inflation and Economic Uncertainty, According to S&P/Case-Shiller Index

23 Aug 2026, 23:11 UTC

U.S. GDP Price Index QoQ 2nd Estimate Set for August 26, Forecasting a 0.063% Increase Amid Inflation Concerns and Mixed Market Sentiment

23 Aug 2026, 23:11 UTC

South Africa's Trade Balance Data Release on August 28 Expected Amid Fluctuating Trends and Commodity Market Sentiment.

23 Aug 2026, 23:01 UTC

Correlated Moves

Gold/Silver is trading lower, influenced by broader market sentiment and concerns over the U.S. national debt reaching $40 trillion. It remains below its 20-day moving average.

23 Aug 2026, 23:01 UTC

Gold/NZD is trading higher since Friday's close, maintaining a position above its 20-day moving average amid concerns over the U.S. national debt reaching $40 trillion.

23 Aug 2026, 23:01 UTC

Gold/JPY is trading higher, reflecting a broader positive performance. The asset remains significantly above its 20-day moving average, indicating strong underlying momentum.

23 Aug 2026, 23:01 UTC

Gold/HKD is higher today, reflecting a strong trend above its 20-day moving average. Earlier, it reached a high of 2.16% above Friday's close.

23 Aug 2026, 23:01 UTC

Gold/SGD is higher in the current session, maintaining a gain above its 20-day moving average despite a slight pullback from earlier peaks.

Peer Comparison

Price change

Pharming Group NV Forecast

Rating Consensus

By TipRanks

0 ratings

Buy

Hold

Sell

Based on 0 analysts giving stock ratings to Pharming Group NV - Dist in the past 3 months.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.